-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Hold on AnaptysBio, Raises Price Target to $50

Benzinga·03/09/2026 12:09:14
Listen to the news
Truist Securities analyst John Lee maintains AnaptysBio (NASDAQ:ANAB) with a Hold and raises the price target from $36 to $50.